Telmisartan Drug Asset Due Diligence Report 2026

This Telmisartan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

401

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Telmisartan can convert its Small molecule drug profile and AT1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Telmisartan (query alias: telmisartan)
Modality / target	Small molecule drug; AT1R; AT1R antagonists
Highest global status	Approved
Originator	Boehringer Ingelheim GmbH
Active developers	Actavis Group PTC ehf, BCWORLD PHARM. Co., Ltd., KRKA dd

The MCP disease footprint includes Cardiovascular Diseases, Essential Hypertension, Hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07547878	Phase 4	Not yet recruiting	64	On-study retention rate at 6 months
NCT07588932	Early Phase 1	Recruiting	50	Fugl-Meyer Assessment - Upper Extremity (FMA-UE)
NCT07652567	Not Applicable	Completed	690	1.New-onset hypertension and new-onset diabetes. 2.Composite cardiovascular events (fatal and non-fatal stroke, myocardial infarction, cardiovascular death, and coronary revascularization).

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Characterization of Arterial Hypertension and Efficacy of Blood-pressure Lowering Therapy at Different Altitudes Above Sea Level

Phase 4; n=166; evaluation: not stated. Reported fields: -; Change is 24-hour Systolic Blood Pressure From Baseline to 4 Weeks(Mean) = -5.9 mmHg (Standard Deviation, 8.4); -

FDA-Approved Drugs-WIDAPLIK-CLINICAL STUDIES(II)

Phase 3; n=not disclosed; evaluation: Positive. Reported fields: SBP(12-week) = 0.5 mmHg (SE, 0.4); SBP(12-week) = -1.5 mmHg (SE, 0.5); SBP(12-week) = -4.0 mmHg (SE, 0.5)

EFFICACY AND SAFETY OF LOW-DOSE ANTIHYPERTENSIVE COMBINATION DRUGS INCLUDING AMLODIPINE, TELMISARTAN, AND CHLORTHALIDONE: A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PARALLEL, PHASE

Phase 2; n=221; evaluation: Positive. Reported fields: -; ADR = 14.0 Pts ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Telmisartan addresses Cardiovascular Diseases, Essential Hypertension, Hypertension. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 43 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: AT1R records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-03-16	George Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreement	Phase 3	Financial terms not disclosed
2026-03-11	George Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea	Phase 3	Financial terms not disclosed
2026-02-25	George Medicines advances its global commercial strategy for GMRx2 with an exclusive licensing agreement with Orient EuroPharma in Southeast Asia	Phase 3	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more SGLT-2 inhibitors and pimobendan and/or telmisartan”. The milestone feed surfaced a patent-application signal described as “Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan”. The milestone feed surfaced a patent-application signal described as “Preparation method of telmisartan”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO